Ann: ACW updated depression trial results and implications, page-46

Yes, precisely.

You would also want to adjust for between group differences. For example, more difficult to treat patients in the placebo group could heavily skew the data in favor of treatment arm, and vice versa.

Monotherapy endpoint not signifcant at 95% (p = 0.06) compared to no therapy as per first P2 data announcement. Once again, need to understand the severity of depression to conceptualize findings.

Monotherapy data indicates effect declines from 6 weeks to 10 weeks, but combination data suggests improvements from 6 to 10 weeks. Pretty clear that the improvement in effect is related to SoC and not treatment.